Imaging and CSF analyses effectively distinguish CJD from its mimics.

Distinguishing sporadic Creutzfeldt-Jakob disease (sCJD) from other neurodegenerative conditions remains a diagnostic challenge. While clinical features overlap, no single marker reliably separates sCJD from its mimics. Prior research has shown that diffusion-weighted MRI and CSF biomarkers are commonly used but have limited specificity. This gap motivated a detailed review of diagnostic accuracy in a specialist prion clinic setting. No prior work had resolved how best to combine imaging and CSF data for definitive classification. The uncertainty persists in clinical settings where early diagnosis is critical. This study aimed to address that uncertainty by analyzing diagnostic outcomes in a large cohort. The goal was to identify the most effective diagnostic tools for sCJD versus mimics.

This study aimed to compare clinical and diagnostic features of patients with confirmed sCJD against those with alternative diagnoses referred to a specialist prion clinic. The specific problem addressed was the lack of a definitive diagnostic test to distinguish sCJD from its mimics. The motivation stemmed from the need to improve diagnostic accuracy in clinical practice. The study focused on evaluating the utility of MRI and CSF tests in this distinction. It also aimed to identify the most common alternative diagnoses in CJD mimic cases. The researchers sought to determine which tests provided the highest diagnostic confidence. They focused on diffusion-weighted MRI and CSF RT-QuIC as potential diagnostic tools. The goal was to provide evidence for clinical decision-making in prion disease diagnosis.

The study reviewed data from 214 patients with confirmed sCJD and 50 patients with alternative diagnoses from the UK National Prion Monitoring Cohort Study. Clinical features, imaging, and CSF data were compared between the two groups. Patients were selected based on postmortem confirmation of sCJD or alternative diagnoses. The study spanned from October 2008 to November 2015. Clinical features such as myoclonus and hallucinations were assessed for frequency. Diffusion-weighted MRI scans were analyzed for diagnostic accuracy. CSF biomarkers including 14-3-3 protein and S100B were measured. The RT-QuIC test was introduced during the study period and applied to CSF samples.

Diffusion-weighted MRI correctly classified 92% of sCJD cases and only 2% of CJD mimics. This finding suggests MRI is a highly specific test for sCJD. The CSF RT-QuIC test was positive in 89% of sCJD cases and 0% of mimics. This result indicates strong diagnostic value for RT-QuIC. Clinical features like myoclonus and hallucinations were more frequent in sCJD but not reliable for individual diagnosis. Alzheimer’s disease and dementia with Lewy bodies were common alternative diagnoses. Ten percent of CJD mimics had immune-mediated encephalopathy. Lymphoma and progressive multifocal leukoencephalopathy were also observed in mimic cases. The combination of MRI and RT-QuIC achieved perfect classification in this study.

The authors propose that diffusion-weighted MRI and CSF RT-QuIC are the most effective tools for distinguishing sCJD from its mimics. These findings suggest that combining these two tests improves diagnostic accuracy. The study supports the use of RT-QuIC as a new standard in CJD diagnosis. The results indicate that clinical features alone are insufficient for reliable diagnosis. The authors emphasize the importance of MRI and RT-QuIC in clinical decision-making. They suggest that these tests should be used together for definitive classification. The study does not propose new diagnostic tools or future research directions. The conclusions are based on observed diagnostic performance in the cohort.